

09/936562

Sim & McBurney

Patent and Trade-mark Agents

Please Quote
Our ref. 1038-1190 MIS/ac

Your ref.

Writer's Ext. 239

E-mail: mistewart@sim-mcburney.com

November 30, 2001

VIA COURIER


The Commissioner of Patents
and Trademarks
Washington, D.C. 20231
United States of America

Dear Sirs:

RE: U.S. Patent Application No. 09/936,362
Filing Date: March 16, 2000
Applicant: Sheena Loosmore et al
RECOMBINANT HAEMOPHILUS INFLUENZA
ADHESIN PROTEINS

Please find enclosed an Information Disclosure Statement and copies of the references listed therein with respect to each of the references cited in the specification, in the International Search Report received on the corresponding International application and in prior U.S. application No. 09/936,362.

Respectfully submitted,


Michael I. Stewart
Registration No. 24,973

M.I. Stewart/ac
End.

JPGS Rec'd 12/3/01 DEC 03 DEC 2001

3.0 University Avenue
6th floor
Toronto, Canada
M5C 1R7

Telephone (416) 595-1155
Fax (416) 595-1163



JECH CENTER 1600 2900

FEB 06 2002

RECEIVED

IDS/#6
PQ T 2/8/02

MICHAEL I. STEWART
ROGER T. HUGHES, Q.C.
TONI POLSON ASHTON
JOHN H. WOODLEY
KENNETH D. MCKAY
TIMOTHY M. LOWMAN
STEPHEN M. LANE
ARTHUR B. RENAUD
STEPHEN J. PERRY
PATRICIA A. RAE
DAVID A. RUSTON
L.E. TRENT HORNE
LOLA A. BARTOSZEWSKI
THOMAS T. RIEDER
WARREN J. GALLOWAY
URSULA M. MCQUINN
ROBERT C.T. LIANG
ELIZABETH VALENTINA
LESLIE M. MORRISON
GEOFFREY B.C. DE KLEINE
SENIOR CONSULTANTS
PETER W. MCBURNEY
BRENDA L. BOARDMAN
TECHNICAL ASSISTANTS
KIMBERLY A. MCMANUS, PH.D.
WENDY M. NOSS, B.A., L.L.B.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JG/

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 1038-1190 MIS:ac	SERIAL NO. 09/936,362
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT: Sheena Loosmore et al.	
DEC 03 2001 OFFICE OF PATENT & TRADEMARK OFFICE		FILING DATE March 16, 2000	GROUP ---

RECEIVED

FEB 06 2002

TECH CENTER 60024008

U.S. PATENT DOCUMENTS

*INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCL.	FILED DATE
	4,496,538	Jan/85	Gordon	424	92	
	5,808,024	Sep. 15, 1998	Sasaki et al.	536	23.1	
	4,855,283	Aug. 8, 1989	Lockhoff	424	27.8	
	4,952,496	Aug. 28, 1990	Studier	435	91	
	4,258,029	Mar. 24, 1981	Moloney	424	88	
	5,646,259	July 8, 1997	St. Geme III	536	23.1	
	5,194,254	Mar. 16, 1993	Barber	424	85.8	
	5,843,463	Dec. 1, 1998	Krivan	424	256.1	

FOREIGN PATENT DOCUMENTS

DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCL.	TRANSLATION	
WO 95/34308	Dec. 21, 1995	PCT			YES	NO
WO 96/30519	Oct. 3, 1996	PCT				
WO 96/02648	Feb. 1, 1996	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

1 ✓	Berkowitz et al. 1987. J. Pediatr. 110:509.
2	Claesson et al. 1989. J. Pediatr. 114:97.
3 ✓	Black, S.B., H.R. Shinefield, B. Fireman, R. Hiatt, M. Polen, E. Vittinghoff, The Northern California Kaiser Permanent Vaccine Study Center Pediatrics Group. Efficacy in infancy of oligosaccharide conjugate <i>Haemophilus influenzae</i> type b (HbOC) vaccine in a United States population of 61,080 children. 1991. Pediatr. Infect. Dis. J. 10:97-104.
4 ✓	Madore, D.V. 1996. Impact of immunization on <i>Haemophilus influenzae</i> type b disease. Infectious Agents and Disease 5:8-20.
5 ✓	Bluestone, C.D. 1982. Current concepts in otolaryngology. Otitis media in children: to treat or not to treat? N. Engl. J. Med. 306:1399-1404.

EXAMINER:

/s/ Jennifer Granger/

DATE CONSIDERED:

10/06/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JG/

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JG/

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 1038-1190 MIS:ac	SERIAL NO. 09/936,362
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT: Sheena Loosmore et al.	
		FILED DATE Mach 16, 2000	GROUP ---



TECH CENTER 16002800

FEB 06 2002

RECEIVED

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
6 ✓	St. Geme, J.W. and D. Cutter. (1995) Evidence that surface fibrils expressed by <i>Haemophilus influenzae</i> type B promote attachment to human epithelial cells. <i>Molec. Microbiol.</i> 15:77-85.
7 ✓	Barenkamp, S.J., and E. Leininger. 1992. Cloning, expression, and DNA sequence analysis of genes encoding nontypeable <i>Haemophilus influenzae</i> high-molecular-weight surface-exposed proteins related to filamentous hemagglutinin of <i>Bordetella pertussis</i> . <i>Infect. Immun.</i> 60:1302-1313.
8 ✓	Barenkamp, S.J. and J.W. St. Geme. (1996) Identification of a second family of high-molecular-weight adhesion proteins expressed by non-typable <i>Haemophilus influenzae</i> . <i>Molec. Microbiol.</i> 19:1215-1223.
9 ✓	St. Geme, J.W. D. Cutter, and S.J. Barenkamp. (1996) Characterization of the genetic locus encoding <i>Haemophilus influenzae</i> type b surface fibrils. <i>J. Bact.</i> 178:6281-6287.
10 ✓	St. Geme III, J.W., S. Falkow, and S.J. Barenkamp. 1993. High-molecular-weight proteins of nontypeable <i>Haemophilus influenzae</i> mediate attachment to human epithelial cells. <i>Proc. Natl. Acad. Sci. USA</i> 90:2875-2879.
11 ✓	Barenkamp, S.J. 1996. Immunization with high-molecular-weight adhesion proteins of nontypeable <i>Haemophilus influenzae</i> modifies experimental otitis media in chinchillas. <i>Infect. Immun.</i> 64:1246-1251.
12 ✓	Tabor, S., and C.C. Richardson. 1985. A bacteriophage T7 RNA polymerase/promoter system for controlled exclusive expression of specific genes. <i>Proc. Natl. Acad. Sci. USA</i> 82:1074-1078.
13 ✓	Patient, M.E., and D.K. Summers. 1993. ColE1 multimer formation triggers inhibition of <i>Escherichia coli</i> cell division. <i>Molec. Microbiol.</i> 9:1089-1095.
14 ✓	Yang, Y.-P., S.M. Loosmore, B. Underdown, and M.H. Klein. 1998. Nasopharyngeal colonization with nontypeable <i>H. influenzae</i> in chinchillas. <i>Infect. Immun.</i> 66:1973-1980.
15 ✓	O'Hagan, D.T. 1992. Oral delivery of vaccines. Formulation and clinical pharmacokinetic considerations. <i>Clin. Pharmacokinet</i> 22(1): 1-10.
16	Ulmer et al. 1993. <i>Curr. Opin. Invest. Drugs</i> 2:983-989.
17 ✓	Lockhoff, O., 1991. Glycolipids as immunomodulators: Synthesis and properties.
18 ✓	Nixon-George A., et al., 1990. The adjuvant effect of stearyl tyrosine on a recombinant subunit hepatitis B surface antigen. <i>J. Immunol</i> 144 (12):4798-4802.
19 ✓	Laemmli, U.K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. <i>Nature</i> 227:680-685.
EXAMINER:	/Jannifer Granger/
DATE CONSIDERED:	10/06/2008

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant. //JG/

